Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
16 oct. 2024 07h00 HE
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
12 sept. 2024 07h00 HE
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
19 août 2024 07h00 HE
|
Apogee Therapeutics, LLC
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in...
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
28 mai 2024 07h30 HE
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
TRUGOLF RELEASES GROUNDBREAKING E6 APEX RANGE TRAINING SOFTWARE AND SIGNS JOE HALLETT, PGA COACH OF THE YEAR
08 avr. 2024 09h00 HE
|
TruGolf Holdings, Inc.
SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc.(Nasdaq: TRUG) ("TruGolf”), among the leading sellers and distributors of golf simulator software and hardware, today...
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
07 mars 2024 18h49 HE
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for...
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
05 mars 2024 06h10 HE
|
Apogee Therapeutics, LLC
Positive interim results from APG777 Phase 1 healthy volunteer clinical trial exceeded objectives with approximately 75-day half-life which supports the potential for higher exposures leading to...
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
07 août 2023 07h30 HE
|
Apogee Therapeutics, LLC
Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care, including the potential for every two- or three-month dosing Initial subcutaneous...
Apogee Therapeutics to Participate in Upcoming August Investor Conferences
02 août 2023 07h30 HE
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic...
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
18 juil. 2023 16h01 HE
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic...